International AIDS Vaccine Initiative & AstraZeneca
3 shared events · Importance 3 · Last updated Jun 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative (IAVI) received an initial $3.2 million from CEPI to develop a single-dose Bundibugyo vaccine candidate using technology similar to Merck's Ervebo.
AstraZeneca: AstraZeneca is mentioned in the context of the University of Oxford's vaccine technology, which is similar to their COVID-19 vaccine.
May 22, 2026 · 36 articles
Accidents
International AIDS Vaccine Initiative: Developing a single-dose Bundibugyo vaccine candidate, which is being prioritized for clinical evaluation. Their work could provide an alternative vaccine.
AstraZeneca: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.
Mar 09, 2018 · 543 articles
Accidents
International AIDS Vaccine Initiative: The International AIDS Vaccine Initiative is developing a Bundibugyo-specific version of a vaccine using a platform similar to Merck & Co.'s Ervebo vaccine, contributing to the search for a treatment.
AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.
May 18, 2026 · 505 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how International AIDS Vaccine Initiative and AstraZeneca interact across events, view sentiment trends, and discover connected entities.
Open Dashboard